Extramedullary multiple myeloma

Leukemia and Lymphoma

Volumn 54, Issue 6, 2013, Pages 1135-1141

  Weinstock, Matthew ^a   Ghobrial, Irene M ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Extramedullary; Multiple myeloma; Plasmacytoma

Indexed keywords

ANGIOPOIETIN 1; BORTEZOMIB; CD31 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR4; DEXAMETHASONE; DOXORUBICIN; FOCAL ADHESION KINASE; GELATINASE B; HEMOGLOBIN; HERMES ANTIGEN; LACTATE DEHYDROGENASE; LENALIDOMIDE; M PROTEIN; PADGEM PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POMALIDOMIDE; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; THALIDOMIDE; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 4; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL INFILTRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOGENETICS; DRUG EFFICACY; EXTRAMEDULLARY MULTIPLE MYELOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; LOW DRUG DOSE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PLASMA CELL; PLASMACYTOMA; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SOFT TISSUE TUMOR; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; HUMANS; IMMUNOPHENOTYPING; INCIDENCE; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 84877732000     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.740562     Document Type: Review

References (38)

1. Van Rhee F, Anaissie E, Angtuaco E, et al., editors . Williams hematology . 8th ed . New York, NY: McGraw Hill; 2010.
2. Rajkumar SV, Blood E, Vessole D, et al . Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group . J Clin Oncol 2006; 24 : 431 - 436.
3. Dimopoulos M, Spencer A, Attal M, et al . Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma . N Engl J Med 2007; 357 : 2123 - 2132.
4. R ichardson P.G.S onneveld P, S chuster M W, et a l. B ortezomib or high-dose dexamethasone for relapsed multiple myeloma . N Engl J Med 2005; 352 : 2487 - 2498.
5. A ttal M, H arousseau J L, S toppa A M, et a l. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma . Intergroupe Francais du Myelome. N Engl J Med 1996; 335 : 91 - 97.
6. Short KD, Rajkumar SV, Larson D, et al . Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011; 25: 906- 908.
7. V arettoni M, C orso A, P ica G, et a l. I ncidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients . Ann Oncol 2010; 21 : 325 - 330.
8. Blade J, Kyle RA, Greipp PR . Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93 : 345 - 351.
9. Dawson MA, Patil S, Spencer A . Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains . Haematologica 2007; 92: 143- 144.
10. Cerny J, Fadare O, Hutchinson L, et al . Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol 2008; 81 : 65 - 69.
11. Pasmantier MW, Azar HA . Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases . Cancer 1969; 23 : 167 - 174.
12. B lade J, L ust J A, K yle R A. I mmuglobulin D multiple myeloma: Presenting features, reponse to therapy, and survival in a series of 53 cases . J Clin Oncol 1994; 12 : 2398 - 2404.
13. Bartel TB, Haessler J, Brown TL, et al . F-18 fl uorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma . Blood 2009; 114 : 2068 - 2076.
14. Blade J, Fernandez de Larrea C, Rosinol L, et al . Soft-tissue plasmacytomas in multiple myeloma: Incidence, mechanisms of extramedullary spread, and treatment approach . J Clin Oncol 2011; 29 : 3805 - 3812.
15. C hang H, S loan S, L i D, et a l. M ultiple myeloma involving central nervous system: High frequency of chromosome 17p13.1 (p53) deletions . Br J Haematol 2004; 127 : 280 - 284.
16. Sheth N, Yeung J, Chang H . p53 nuclear accumulation is associated with extramedullary progresson of multiple myeloma. Leuk Res 2009; 33: 1357- 1360.
17. Billecke L, Penas EM, May AM, et al . Similar incidences of TP53 deletions in extramedullary organ infi ltrations, soft tissue and osteolyses of patients with multiple myeloma . Anticancer Res 2012; 32 : 2031 - 2034.
18. Egan JB, Shi CX, Tembe W, et al . Whole genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution and clonal tides . Blood 2012; 120 : 1060 - 1066.
19. Wang SY, Hao HL, Deng K, et al . Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infi ltration . Leuk Lymphoma 2012; 53: 1162- 1168.
20. R asmussen T, K uehl M, L odahl M, et a l. P ossible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors . Blood 2005; 105 : 317 - 323.
21. Blade J, Fernandez de Larrea C, Rosinol L, et al . Soft-tissue plasmacytomas in multiple myeloma: Incidence, mechanisms of extramedullary spread, and treatment approach . J Clin Oncol 2011; 29 : 3805 - 3812.
22. Hedvat CV, Comezo RL, Teruya-Feldstein J, et al . Insights into extramedullary tumor cell growth revealed by expression profi ling of human plasmacytomas and multiple myeloma . Br J Haematol 2003; 122 : 728 - 744.
23. Dahl IM, Rasmussen T, Kauric G, et al . Diff erential expression of CD56 and CD44 in the evolution of extramedullary myeloma . Br J Haematol 2002; 116 : 273 - 277.
24. Chang H, Bartlett E, Patterson B, et al . The absence of CD56 on the malignant plasma cells in the cerebrospinal fl uid is the hallmark of multiple myeloma involving central nervous system . Br J Haematol 2005; 129 : 539 - 541.
25. Blade J, Fernandez de Larrea C, Rosinol L, et al . Soft-tissue plasmacytomas in multiple myeloma: Incidence, mechanisms of extramedullary spread, and treatment approach . J Clin Oncol 2011; 29 : 3805 - 3812.
26. Bink K, Haralambieva E, Kremer M, et al . Primary extramedullary plasmacytoma: Similarities and differences with multiple myeloma revealed by interphase genetics . Haematologica 2008; 93 : 623 - 626.
27. Rasche L, Bernard C, Topp M, et al . Features of extramedullary myeloma relapse: High proliferation, minimal marrow involvement, adverse cytogenetics: A retrospective single-center study of 24 cases. Ann Hematol 2012; 91 : 1031 - 1037.
28. Raanani P, Shpilberg O, Ben-Bassat I . Extramedullary disease and targeted therapies for hematological malignancies - is the association real? Ann Oncol 2007; 18 : 7 - 12.
29. Barlogie B, Smallwood L, Smith T, et al . High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma . Ann Intern Med 1989; 110 : 521 - 525.
30. Usmani SZ, Heuck C, Mitchell A, et al . Extramedullary disease portends poor prognosis in multiple myeloma and is over represented in high risk disease even in the era of novel agents . Haematologica 2012; 97 : 1761 - 1767.
31. B lade J, P erales M, R osinol L, et a l. Th alidomide in multiple myeloma: Lack of response of soft-tissue plasmacytomas . Br J Haematol 2001; 113 : 422 - 424.
32. Rosinol L, Cibeira MT, Blade J, et al . Extramedullary multiple myeloma escapes the effect of thalidomide . Haematologica 2004; 89 : 832 - 836.
33. N akazato T, M ihara A, I to C, et a l. L enalidomide is active for extramedullary disease in refractory multiple myeloma . Ann Hematol 2012; 91 : 473 - 474.
34. R osinol L, C ibeira M T, U riburu C, et a l. B ortezomib: An eff ective agent in extramedullary disease in multiple myeloma . Eur J Haematol 2006; 76 : 405 - 408.
35. Oriol A . Multiple myeloma with extramedullary disease . Adv Ther 2011; 28(Suppl. 7): 1- 6.
36. Wu P, Davies FE, Boyd K, et al . The impact of extramedullary disease at presentation on the outcome of myeloma . Leuk Lymphoma 2009; 50 : 230 - 235.
37. Trullemans F, Schots R, Storme G, Van Camp B . Late and localized extramedullary relapse of light chain kappa myeloma after syngeneic bone marrow transplantation . Bone Marrow Transplant. 2000; 25(1) : 115 - 7.
38. Chong G, Byrnes G, Szer J, et al . Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy . Bone Marrow Transplant 2000; 26 : 1011 - 1015.